PubMed Health⌕ Search

PubMed · 1784915

[Psoriatic rheumatism].

Abstract

Five to seven per cent of patients with cutaneous psoriasis develop a seronegative inflammatory arthritis which is often erosive and frequently both peripheral and axial. The most common peripheral type of psoriatic arthritis is represented by asymmetrical oligoarthritis, the localisation most suggestive of psoriasis being distal interphalangeal arthritis. Symmetrical polyarthritis may also be observed. Severe and mutilating forms of the disease are fortunately rare. Te axial type of psoriatic arthritis consists of a usually bilateral sacroiliitis and/or spinal lesions which may result in ankylosing spondylitis. Most cases of psoriatic arthritis are treated with non-steroidal anti-inflammatory drugs alone and local treatments. Corticosteroid therapy must be administered with caution and restricted to the severe forms. A fairly large number of maintenance treatments for peripheral arthritis have been used, not always after controlled trials; the most commonly prescribed are gold salts, sulphasalazine and methotrexate.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

T Bardin. 1991-10-15. [Psoriatic rheumatism].. https://pubmed.ncbi.nlm.nih.gov/1784915/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Vanishing finger in psoriatic arthritis: a case report.

Dactylitis is a typical phenomenon in psoriatic arthritis, presenting as a "sausage-shaped" finger. Although classically the distal interphalangeal joints are affected, proximal interphalangeal joints and metacarpophalangeal joints are frequently involved. We present a patient who presented with severe psoriatic arthritis of the proximal interphalangeal joint, leading to subtotal disappearance of the phalangeal bones and important shortening of the fourth finger after 10 years of evolution.

Arthritis, Psoriatic↗

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

OBJECTIVE: To compare the prevalence of cardiovascular diseases and their risk factors between patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) and control subjects. METHODS: Data for patients continuously enrolled in an integrated outcomes database between January 1, 2001, and December 31, 2002, with International Classification of Diseases, 9th Revision codes of 714.x (RA), 696.0 (PsA), or 720.0 (AS) were evaluated in this cross-sectional comparative study. Control groups were established for each patient group (1:4 ratio) by matching on the basis of age, sex, geographic region, and length of time in plan. Age- and sex-adjusted prevalence of cardiovascular comorbidities and risk factors were calculated; the prevalence ratio of the comorbidities and risk factors for the patient groups compared with the control population were estimated. Use of selected cardiovascular medications was also compared between patient and control groups. RESULTS: The RA, PsA, and AS cohorts comprised 28,208, 3066, and 1843 patients, respectively. The prevalence ratio of ischemic heart disease (1.5, 1.3, 1.2), atherosclerosis (1.9, 1.4, 1.5), peripheral vascular disease (2.4, 1.6, 1.6), congestive heart failure (2.0, 1.5, 1.8), cerebrovascular disease (1.6, 1.3, 1.7), type II diabetes (1.4, 1.5, 1.2), hyperlipidemia (1.2, 1.2, 1.2), and hypertension (1.3, 1.3, 1.3) were higher in patients than controls. For RA, PsA, and AS, use of angiotensin-converting enzyme inhibitors, calcium channel blockers, diuretics, nitrates/vasodilators, anticoagulants, and antihyperlipidemia agents was significantly higher in patients than controls. CONCLUSION: Cardiovascular diseases and their risk factors were more common in patients with RA, PsA, and AS than in matched controls.

Arthritis, Psoriatic↗

Therapies for psoriatic nail disease. A systematic review.

Nail involvement is common in patients with psoriasis and psoriatic arthritis, affecting 80%-90% of patients at some time. It also has significant effects on quality of life. Psoriatic nail disease can be refractory to treatment, and different features may respond variably to different therapies. The lack of standardized outcome assessments hinders the interpretation of available data. In this systematic evidence-based review of the literature, we assess various treatments for psoriatic nail disease.

Arthritis, Psoriatic↗